Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
409 stopped studies mapped to Mature B-Cell Non-Hodgkin Lymphoma and descendants · 88% state a reason
Over the 409 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05431179 | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell… | Phase 3 | withdrawn | Jun 24, 2022 | Oncternal Therapeutics, Inc | Due to a strategic reprioritization based on the rapidly changing clinical and commercial landscape… | Sponsor / business decision |
| NCT04236141 | A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With… | Phase 3 | terminated | Jan 22, 2020 | Hoffmann-La Roche | Sponsor's decision, no safety concerns | Safety / toxicity |
| NCT03370185 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic…(BRIO) | Phase 2 | withdrawn | Dec 12, 2017 | SecuraBio | Reassessing corporate priorities. | Other (stated, no rule matched) |
| NCT02292225 | Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi… | Phase 1 | terminated | Nov 17, 2014 | SecuraBio | The scope of the program has been reduced to focus resources on studies which can potentially… | Other (stated, no rule matched) |
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | Phase 1 | withdrawn | Jan 4, 2022 | Hutchmed | HUTCHMED has decided to discontinue the HMPL 760 study. | Other (stated, no rule matched) |
| NCT03123393 | TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | terminated | Apr 21, 2017 | Calithera Biosciences, Inc | Lack of efficacy of the drug; no safety concern | Safety / toxicity |
| NCT03876028 | Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell… | Phase 1 | terminated | Mar 15, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for… | Phase 1 | withdrawn | Feb 8, 2022 | Fred Hutchinson Cancer Center | PI left institution and funding sponsor closed study. Study did not open to accrual, and no… | Investigator |
| NCT00096460 | Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent… | Phase 2 / Phase 3 | terminated | Nov 10, 2004 | Medical College of Wisconsin | lower than anticipated accrual | Enrollment / accrual |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | Phase 1 | terminated | Mar 4, 2021 | Samus Therapeutics, Inc. | Samus Therapeutics Company Closure | Sponsor / business decision |
| NCT01416428 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic… | Phase 1 / Phase 2 | terminated | Aug 15, 2011 | Amgen | A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of… | Safety / toxicity |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant… | Phase 1 / Phase 2 | terminated | Aug 7, 2020 | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | Study terminated early due to business decision. | Sponsor / business decision |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute…(LABMI) | Phase 4 | terminated | Dec 1, 2015 | University Hospital, Angers | recruitment difficulties | Enrollment / accrual |
| NCT04635683 | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory… | Phase 1 | withdrawn | Nov 19, 2020 | Yazeed Sawalha | Investigational Drug removed from the market | Other (stated, no rule matched) |
| NCT02225275 | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic… | Phase 2 | terminated | Aug 26, 2014 | M.D. Anderson Cancer Center | Due to slow accrual | Enrollment / accrual |
| NCT02531308 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)(DLBCL) | Phase 2 | terminated | Aug 24, 2015 | Rush University Medical Center | poor accrual | Enrollment / accrual |
| NCT02572453 | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL | Phase 2 | terminated | Oct 9, 2015 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT02698189 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons | Safety / toxicity |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT02706405 | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell… | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT03422523 | Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or…(ARGO) | Phase 2 | terminated | Feb 5, 2018 | University Hospital Southampton NHS Foundation Trust | Failure to reach pre-specified futility boundary | Efficacy / futility |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or…(MT-3724NHL001) | Phase 1 / Phase 2 | terminated | Feb 11, 2015 | Molecular Templates, Inc. | Sponsor decision following clinical hold | Sponsor / business decision |
| NCT03488251 | PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and… | Phase 2 | terminated | Apr 4, 2018 | Molecular Templates, Inc. | Sponsor decision | Sponsor / business decision |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell… | Phase 1 / Phase 2 | suspended | Oct 15, 2018 | Northwestern University | Protocol being amended for stats/accrual changes as per PI | Enrollment / accrual |
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With… | Phase 2 | withdrawn | Dec 11, 2020 | Academic and Community Cancer Research United | Permanently closed 11/19/201. The widespread availability of COVID vaccination, the projected… | COVID-19 / pandemic |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without…(UNITY-NHL) | Phase 2 / Phase 3 | terminated | Jun 8, 2016 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT01241786 | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for…(VZCLLPI0146) | Phase 2 | terminated | Nov 16, 2010 | Hackensack Meridian Health | The study was closed early due to poor accrual | Enrollment / accrual |
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in… | Phase 3 | withdrawn | Mar 15, 2021 | Incyte Corporation | This study was withdrawn due to a business decision. | Sponsor / business decision |
| NCT04836832 | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin… | Phase 1 | withdrawn | Apr 8, 2021 | Narendranath Epperla | PI decision | Other (stated, no rule matched) |
| NCT02374424 | Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients(GIOTTO) | Phase 2 | terminated | Feb 27, 2015 | Fondazione Italiana Linfomi - ETS | Interim analysis planned as per protocol didn't provide positive outcome therefore enrollment was… | Efficacy / futility |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | Phase 1 | terminated | Apr 14, 2021 | Eden BioCell Ltd. | CAR-T manufacturing technology can not meet the dose requirement for clinical patients. | Drug supply |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | Phase 1 | terminated | Dec 7, 2012 | TG Therapeutics, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT04535102 | POLA+BR for Relapsed or Refractory DLBCL | Phase 2 | withdrawn | Sep 1, 2020 | University of Colorado, Denver | Lack of sufficient patient population | Other (stated, no rule matched) |
| NCT04849715 | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab…(CITADEL-310) | Phase 3 | withdrawn | Apr 19, 2021 | Incyte Corporation | business decision; no enrolled patients | Enrollment / accrual |
| NCT04155840 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic… | Phase 2 | terminated | Nov 7, 2019 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's… | Phase 1 / Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | Per PI Request | Other (stated, no rule matched) |
| NCT04974996 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of…(LOTIS-8) | Phase 1 | withdrawn | Jul 23, 2021 | ADC Therapeutics S.A. | Decision to not proceed with study. | Other (stated, no rule matched) |
| NCT02356458 | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | Phase 1 / Phase 2 | terminated | Feb 5, 2015 | Swiss Cancer Institute | SAKK Board decision of 14th November 2020 due to financial reasons. | Funding |
| NCT04990778 | Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell… | Phase 2 | withdrawn | Aug 4, 2021 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04209621 | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | terminated | Dec 24, 2019 | National Heart, Lung, and Blood Institute (NHLBI) | Due to unexpected sudden death on study. | Other (stated, no rule matched) |
| NCT01685606 | Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight…(273) | Phase 2 | terminated | Sep 14, 2012 | Brown University | Lack of accrual and low efficacy | Efficacy / futility |
| NCT04456023 | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse… | Phase 2 | withdrawn | Jul 2, 2020 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT00384111 | Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular… | Phase 3 | terminated | Oct 5, 2006 | Spectrum Pharmaceuticals, Inc | Study was terminated early as per the Sponsor's decision. | Sponsor / business decision |
| NCT04176913 | Study of LUCAR-20S in Patients With R/R NHL | Phase 1 | terminated | Nov 25, 2019 | The First Affiliated Hospital with Nanjing Medical University | Both the sponsors and collaborator are considering terminating the study | Other (stated, no rule matched) |
| NCT01510184 | Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly… | Phase 3 | terminated | Jan 13, 2012 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT03954106 | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen… | Phase 2 | terminated | May 17, 2019 | Jazz Pharmaceuticals | Primary endpoint would unlikely to be met based on the unplanned interim assessment on the first 20… | Efficacy / futility |
| NCT03135262 | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants… | Phase 1 / Phase 2 | terminated | May 1, 2017 | Hoffmann-La Roche | Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2. | Sponsor / business decision |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic… | Phase 1 | terminated | Jan 9, 2019 | AbbVie | Safety | Safety / toxicity |
| NCT03639324 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL(RIVe-CLL/SLL) | Phase 1 | withdrawn | Aug 21, 2018 | Virginia Commonwealth University | Slow Accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 21, 2023source: clinicaltrials